Ewan Cameron, 1976-10: Cameron and Pauling compared 100 terminal cancer patients given 10 g/day of ascorbic acid at Vale of Leven Hospital, Scotland, with 1000 patients they describe as treated identically but without ascorbate, and reported a mean survival more than 4.2 times longer in the treated group.
The mean survival time is more than 4.2 times as great for the ascorbate subjects (more than 210 days) as for the controls (50 days).
Abstract (article pp. 3685-3689)
Ewan Cameron, 1976-10: Cameron and Pauling compared 100 terminal cancer patients given 10 g/day of ascorbic acid at Vale of Leven Hospital, Scotland, with 1000 patients they describe as treated identically but without ascorbate, and reported a mean survival more than 4.2 times longer in the treated group. Funder: not stated in the abstract; the work came from Vale of Leven Hospital (Cameron) and the Linus Pauling Institute of Science and Medicine. Maker: ascorbic acid is a generic vitamin, no manufacturer named. Comparator: retrospective 'matched' controls selected from the same hospital's past patients – not randomised, not concurrent, not blinded. Conflicts: Pauling was a public advocate of megadose vitamin C; no disclosure statement in the paper. Methodological critique that the later Mayo trials were designed to answer: treated and control groups were assembled after the fact. Study type: controlled study.
